NEWS: 公告在东京证券交易所JASDAQ标准市场新上市

表纸
市场调查报告书

封闭式药物传输系统(CSTD):~2026年

Closed System Drug Transfer Devices to 2026

出版商 Greystone Research Associates 商品编码 985625
出版日期 内容资讯 英文
商品交期: 最快1-2个工作天内
价格
封闭式药物传输系统(CSTD):~2026年 Closed System Drug Transfer Devices to 2026
出版日期: 2021年02月02日内容资讯: 英文
简介

近年来,随著人们对这些药物对危害的认识得到了越来越清晰的瞭解,人们对这种被认为对人体有害的药物的管理也越来越受到关注。对于护理人员及其患者而言,减少肿瘤细胞毒性药物暴露的最重要的治疗领域是临床肿瘤学,尽管存在基于治疗性抗体的有前途的新药,但仍会引起多种癌症。用于治疗的抗肿瘤药包括烷基化药和抗代谢药。监管机构和行业在制定旨在保护工人和患者免于意外和意外接触细胞毒性物质的标准和程序方面的努力表明,接触和健康问题之间存在因果关系。

本报告调查和分析了全球封闭式药物转移系统(CSTD)市场,并促进了对细胞毒性药物治疗的主要治疗需求,这是构成细胞毒性药物递送市场和可容纳的市场的主要领域我们分析了在商业和开发阶段CSTD中使用的因素,设计元素和技术,主要公司及其商业模式,以及经济,技术和监管因素对CSTD需求的影响。

目录

  • 封闭药物转移系统(CSTD)的预测
  • 执行摘要
  • 癌症治疗趋势
  • 癌症治疗的演变
  • 化学疗法
  • 免疫疗法
  • 细胞毒性药物的作用演变
  • 重组药物生态系统
  • CSTD市场动态
  • 药房
  • POC(护理点)
  • 技术因素
  • CSDT竞争情况
  • 风险与机遇
  • 细胞毒性药物市场
  • 不断变化的处方因素
  • 封闭式药物转移的设计因素
  • 癌症药物的安全性
  • 材料选择问题
  • 毒品重建
  • 癌症治疗的用途和数量
  • 药物特异性剂量变化和个体剂量
  • CSDT设备性能因素
  • 围攻
  • 测试协议
  • CSDT设备:主要市场领域
  • 教学医院
  • 社区/社区医院
  • 癌症中心/诊所
  • 封闭式药物转移:设备评估
  • 市场评估和预测
  • 区域数据
  • 公司简介
目录
Product Code: CST929F

Technology-driven Patient & Caregiver Safety

The administration of drugs deemed hazardous to humans has been receiving increasing amounts of scrutiny in recent years as the dangers of these substances become more clearly understood. For caregivers and their patients, the therapeutic area that is at the forefront of attempts to mitigate exposure to cytotoxic drugs is clinical oncology, a field that - in spite of promising new drugs based on therapeutic antibodies - continues to rely heavily on antineoplastics, a class that includes alkylating agents and antimetabolites, to treat a wide range of cancers. Regulatory and industry efforts to create standards and procedures designed to protect workers and patients from accidental and incidental exposure to cytotoxics are being driven by data that suggests a causal link between exposure and health issues.

What You Will Learn:

  • What are the key segments and addressable markets that comprise the market for cytotoxic drug delivery?
  • What are the major therapeutic demand drivers for cytotoxic drug therapeutics?
  • What are the design factors and technologies that are being used in commercial and development-stage closed drug transfer systems?
  • What is the market share and product position in the market and what will it look like in 2026?
  • Who are the companies behind the current generation of cytotoxic transfer devices and what are their business models?
  • What is the role of pharma-device alliances and design partnerships in the commercialization and market access of new and emerging closed system drug transfer devices?
  • What is the impact of economic, technology, and regulatory factors on CSDT device demand?

Table of Contents

  • Closed System Drug Transfer Devices to 2026
  • Executive Summary
  • Oncology Drug Trends
  • The Evolution in Oncology Therapeutics
  • Chemotherapy
  • Immunotherapy
  • The Evolving Role of Cytotoxic Drugs
  • The Recombinant Drug Ecosystem
  • CSTD Market Dynamics
  • Pharmacy
  • Point-of-Care
  • Technology Factors
  • CSDT Competitive Landscape
  • Risks and Opportunities
  • The Market for Cytotoxic Drugs
  • Evolving Prescribing Factors
  • Closed System Drug Transfer Design Factors
  • Oncology Therapeutics Medication Safety
  • Material Selection Issues
  • Drug Reconstitution
  • Oncology Drug Administration and Dosing
  • Drug-Specific Dosing Modification and Individualized Dosing
  • CSDT Device Performance Factors
  • Vapor Containment
  • Testing Protocols
  • CSDT Devices - Key Market Segments
  • Teaching Hospitals
  • Regional/Community Hospitals
  • Oncology Centers/Clinics
  • Closed Drug Transfer - Device Assessments
  • Market Assessments and Forecasts
  • Geographic Data
  • Company Profiles